Ukraine government to invest $337 million in domestic pharma
A new state program of the development and preclinical testing of drugs for domestic medicine for the period of 2011-2015 has recently been announced by the government of Ukraine. The implementation of the program is expected to lead to a significant reduction imports of pharmaceuticals to the country, the share if which is currently estimated at 80% of the total market.
The program involves the establishment of a full scientific and technological cycle of production certain drugs, including their preclinical and clinical trials and further launch in mass production. One of the major goals of the program is the development of drugs for the prevention of epidemics as well the creation of diagnostic products in response to bioterrorism.
In addition, as part of the program, the Ukrainian scientists will accelerate efforts in the development of diagnostics, based on microchips, with the aim of identifying cancer at an early stage as well as genetic predisposition to the disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze